Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617.

Eur Urol Open Sci · 2023 · PMC10658415 · PMID 38020530

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A reduction in ctDNA fraction or tumour volume showed a trend for better PSA PFS or OS ( Supplementary Fig. 1 ). 3.3. ctDNA molecular profiles Commonly altered genes and pathways in baseline samples ( n = 31) are summarised in Figure 1 and included AR (65%), TP53 (23%), RB1 (26%), TMPRSS2-ERG (42%), PI3K pathway genes (42%), WNT pathway genes (35%), and DNA repair genes (58%).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.